Companies Agenus Inc
Agenus (AGEN): executive pay, fiscal 2025
Free brief. Every figure links to the company’s own filing.
Velarion Intel: free for 3 days, no card →Email me Agenus Inc’s executive pay brief as a PDF
You get it on this page the moment you ask, and a copy by email. Every figure is cited to its filing.
After the PDF, up to three short notes on the deeper reports for this company. Reply “unsubscribe” to any of them, any time.
CEO pay, last three years
- $5,856,319FY2023
- $3,717,621FY2024
- $1,350,325FY2025
CEO total pay was $1,350,325 in fiscal 2025, down from $3,717,621 in fiscal 2024.
FY2025: salary $715,260 · bonus $429,156 · stock awards $0 · option awards $141,000
Executives and directors
Frequently asked questions
Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.
Full detail
Every table from the filing. Open any section.
Summary compensation table
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Garo Armen | $715,260 | $429,156 | $0 | $141,000 | $0 | $0 | $64,909 | $1,350,325 |
| Chairman and Chief Executive Officer | ||||||||
| Steven O'Day | 594,880 | 297,440 | 0 | 0 | 0 | 0 | 10,500 | 902,820 |
| Chief Medical Officer | ||||||||
| Christine Klaskin | 298,224 | 0 | 0 | 27,257 | 0 | 0 | 6,538 | 332,019 |
| Vice President of Finance | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
Three-year trend — total compensation per named executive
| Named executive officer | FY2025 total | FY2024 total | FY2023 total | Δ FY2024→2025 |
|---|---|---|---|---|
| Garo Armen | $1,350,325 | $3,717,621 | $5,856,319 | ↓ −2,367,296 |
| Steven O'Day | 902,820 | 968,491 | 1,435,980 | ↓ −65,671 |
| Christine Klaskin | 332,019 | 483,477 | 712,747 | ↓ −151,458 |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
Incentive-plan design — the Compensation Discussion & Analysis
Our compensation philosophy emphasizes equity-based incentives that reward long-term performance and align executives' interests with those of stockholders. Fixed compensation (base salary) is balanced against performance-oriented incentives (annual bonus opportunities and multi-year equity awards).
| CEO STI target (% of salary) | 60% |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | Aon Radford |
| Clawback policy | true |
| Anti-hedging | true |
| Anti-pledging | true |
Equity grants and outstanding awards
Grants of plan-based awards — fiscal year 2025
| Executive | Award | Grant date | Threshold | Target | Granted | Maximum | Grant-date fair value |
|---|---|---|---|---|---|---|---|
| Garo Armen | OPTION | 2025-06-17 | — | — | 37,500 | — | $141,000 |
| Christine Klaskin | OPTION | 2025-06-17 | — | — | 7,250 | — | 27,257 |
Vehicle mix — grant-date fair value by award type
| Named executive officer | Time-vested (RSU) | Performance-vested (PSU) | Options / SARs | % performance-vested |
|---|---|---|---|---|
| Garo Armen | $0 | $0 | $141,000 | 0.0% |
| Christine Klaskin | 0 | 0 | 27,257 | 0.0% |
% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.
Outstanding equity awards at fiscal year-end 2025
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Christine Klaskin | Option | 684 | 49 | — |
| Steven O'Day | Option | 841 | 49 | — |
| Christine Klaskin | Option | 1,311 | 13.25 | — |
| Christine Klaskin | Option | 2,619 | 12.26 | — |
| Steven O'Day | Option | 4,189 | 12.26 | — |
| Christine Klaskin | Option | 7,250 | 3.02 | — |
| Garo Armen | Option | 10,050 | 49 | — |
| Garo Armen | Option | 37,500 | 3.02 | — |
| Garo Armen | Option | 45,225 | 11.9 | — |
Director compensation
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Brian CorveseIndependent · Lead Independent Director · Compensation (Chair) · Nominating/Governance · Executive (Chair) | $262,500 | $0 | $112,822 | $0 | $0 | $375,322 |
| Timothy R. WrightIndependent · Audit and Finance · Compensation · Affiliate Transactions · Nominating/Governance · Executive · Audit · Finance | 141,667 | 0 | 57,787 | 0 | 0 | 199,454 |
| Thomas HarrisonIndependent · Audit and Finance (Chair) · Nominating/Governance (Chair) · Audit (Chair) · Finance (Chair) | 110,833 | 0 | 64,208 | 0 | 0 | 175,041 |
| Susan HirschIndependent · Audit and Finance · Compensation · Affiliate Transactions · Audit · Finance | 95,000 | 0 | 55,035 | 0 | 0 | 150,035 |
| Jennifer BuellNot independent · Newly elected | 0 | 0 | 0 | — | 0 | 0 |
| Garo H. ArmenEmployee director · Board Chair · Executive | 0 | 0 | 0 | — | 0 | 0 |
Board fee structure and ownership guideline
| Annual cash retainer | $75,000 |
|---|---|
| Annual equity retainer | $5,000 |
| Per board meeting fee | $1,500 |
| Committee chair fees (audit / comp / nom-gov) | 20,000 / 20,000 / 15,000 |
| Stock ownership guideline | $500 |
Total cost of the board
| Component | FY2025 |
|---|---|
| Cash retainers and fees | $610,000 |
| Equity awards (grant-date value) | $0 |
| All other compensation | $0 |
| Total cost of the board | $610,000 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
Peer group, and who names Agenus as a peer
Companies that benchmark against AGEN
9 companies name AGEN as a compensation peer
- Atara Biotherapeutics, Inc.ATRAFY2024
- Coherus Oncology, Inc.CHRSFY2025
- DYNAVAX TECHNOLOGIES CORPDVAXFY2024
- Evolus, Inc.EOLSFY2025
- Lineage Cell Therapeutics, Inc.LCTXFY2025
- MACROGENICS INCMGNXFY2025
- PUMA BIOTECHNOLOGY, INC.PBYIFY2025
- RIGEL PHARMACEUTICALS INCRIGLFY2025
- Xencor IncXNCRFY2025
Each company listed discloses AGEN in its own benchmarking peer group, as disclosed in each company's most recent proxy statement within the last two proxy seasons. Two companies are therefore absent by design: one that named AGEN in an earlier year and no longer does, and one whose own most recent disclosure is older than the last two seasons.
Disclosed peer group — fiscal year 2025
The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.
Peer reciprocity
The companies Agenus Inc names as compensation peers that name it back in their own disclosed peer groups.
Chief executive pay against the peer group
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company’s own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | iTeos Therapeutics | 2024 | Michel Detheux | $628,684 | $0 | $4,965,264 | $421,014 | $6,085,657 |
| 2 | Precigen | 2025 | Helen Sabzevari | 1,000,000 | 2,215,000 | 1,069,200 | 1,049,997 | 5,354,329 |
| 3 | Inhibrx | 2025 | Mark Lappe | 695,250 | 0 | 0 | 479,723 | 2,892,473 |
| 4 | Voyager Therapeutics, Inc. | 2025 | Alfred Sandrock | 674,903 | 611,900 | 843,900 | 361,917 | 2,508,370 |
| 5 | ALX Oncology | 2025 | Jason Lettmann | 724,500 | 0 | 1,447,488 | 298,856 | 2,470,844 |
| 6 | Repare Therapeutics | 2024 | Lloyd Segal | 630,500 | 278,000 | 1,203,960 | 242,743 | 2,368,837 |
| 7 | Karyopharm Therapeutics Inc. | 2025 | Richard Paulson | 770,000 | 838,996 | 241,544 | 350,350 | 2,320,902 |
| 8 | Instil Bio, Inc. | 2025 | Bronson Crouch | 740,520 | 0 | 1,079,521 | 421,171 | 2,256,412 |
| 9 | Fate Therapeutics, Inc. | 2025 | Bahram Valamehr | 600,000 | 0 | 1,283,868 | 360,000 | 2,248,568 |
| 10 | Precision BioSciences, Inc. | 2025 | Michael Amoroso | 650,875 | 1,025,086 | 0 | 0 | 2,189,467 |
| 11 | MacroGenics, Inc. | 2025 | Eric Risser | 561,568 | 52,000 | 1,049,386 | 251,900 | 2,078,854 |
| 12 | Seres Therapeutics, Inc. | 2025 | Eric Shaff | 408,333 | 0 | 1,338,870 | 0 | 1,775,549 |
| 13 | Immuneering | 2025 | Benjamin Zeskind | 641,493 | 0 | 579,504 | 0 | 1,660,612 |
| 14 | Mersana Therapeutics, Inc. | 2024 | Michael Huber | 632,500 | 133,635 | 518,044 | 322,575 | 1,613,754 |
| 15 | Inovio Pharmaceuticals, Inc. | 2025 | Jacqueline Shea | 728,000 | 346,101 | 351,955 | 144,144 | 1,587,155 |
| 16 | Agenus Inc | 2025 | Garo Armen | 715,260 | 0 | 141,000 | 0 | 1,350,325 |
| 17 | Zentalis Pharmaceuticals, Inc. | 2025 | Julie Eastland | 700,000 | 99,772 | 56,975 | 441,000 | 1,300,731 |
| 18 | Atara Biotherapeutics, Inc. | 2025 | AnhCo Nguyen | 668,800 | 0 | 0 | 0 | 1,068,069 |
Each peer’s compensation is from its most recently filed proxy; fiscal years differ by company. Each peer’s figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
Incentive design against the same peers
| Company | Annual incentive payout | Long-term vehicle mix | PSU measures include TSR | Compensation consultant |
|---|---|---|---|---|
| Agenus Inc | 125% | Options 100 | not disclosed | Aon Radford |
| ALX Oncology | not disclosed | not disclosed | not disclosed | Compensia |
| Atara Biotherapeutics, Inc. | not disclosed | RSU 100 | not disclosed | Pearl Meyer |
| Fate Therapeutics, Inc. | 100% | Options 100 | No | Aon's Human Capital Solutions practice (Radford) |
| Immuneering | not disclosed | Option 100 | not disclosed | Radford, an Aon Company |
| Inhibrx | not disclosed | Option 100 | not disclosed | not disclosed |
| Inovio Pharmaceuticals, Inc. | 33% | not disclosed | Yes — Relative TSR | Aon (Human Capital Solutions practice) |
| Instil Bio, Inc. | not disclosed | Option 100 | not disclosed | FW Cook |
| iTeos Therapeutics | not disclosed | not disclosed | not disclosed | Radford |
| Karyopharm Therapeutics Inc. | 90% | not disclosed | Yes — Relative TSR | Alpine, WTW |
| MacroGenics, Inc. | 85% | not disclosed | not disclosed | Alpine Rewards, LLC |
| Mersana Therapeutics, Inc. | not disclosed | Option 75 · RSU 25 | not disclosed | Pearl Meyer & Partners, LLC |
| Precigen | 140% | not disclosed | not disclosed | Aon |
| Precision BioSciences, Inc. | 115% | RSU 100 | not disclosed | Aon |
| Repare Therapeutics | 70% | not disclosed | not disclosed | Aon |
| Seres Therapeutics, Inc. | not disclosed | Options 100 | not disclosed | Alpine Rewards, LLC |
| Voyager Therapeutics, Inc. | 97.5% | not disclosed | No | Alpine Rewards, LLC |
| Zentalis Pharmaceuticals, Inc. | 105% | not disclosed | not disclosed | Anderson Pay Advisors LLC / Pay Governance LLC |
Read from each company’s Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company’s filing does not state the item.
Say-on-pay history and pay ratio
| Meeting year | Meeting date | For | Against | Abstain | Support | Outcome |
|---|---|---|---|---|---|---|
| 2026 | 2026-06-16 | 12,751,266 | 6,507,225 | 229,289 | 66.21% | Passed |
| 2025 | 2025-06-17 | 5,162,339 | 5,184,095 | 470,628 | 49.89% | Failed |
| 2024 | 2024-06-11 | 8,811,608 | 1,193,315 | 272,010 | 88.07% | Passed |
| 2023 | 2023-06-12 | 181,293,807 | 19,195,313 | 3,828,093 | 90.43% | Passed |
| 2020 | 2020-06-16 | 66,080,495 | 31,700,340 | 435,367 | 67.58% | Passed |
| 2017 | 2017-06-28 | 46,749,347 | 1,471,154 | 158,615 | 96.95% | Passed |
Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year’s compensation.
Say-on-pay — history, company’s computation
| Meeting year | Meeting date | Approval — company’s computation |
|---|---|---|
| 2026 | 2026-06-16 | 66.21%a |
| 2025 | 2025-06-17 | 49.89%b |
| 2024 | 2024-06-11 | 88.07%c |
a. Approved under the standard stated in the filing — “Abstentions and "broker non-votes" will not be counted as votes cast or shares voting on Proposal 4, and will have no effect on the vote.”.
b. Approved under the standard stated in the filing — “Abstentions and broker non-votes will not be counted as votes cast or shares voting on Proposal 2, and will have no effect on the vote.”.
c. Approved under the standard stated in the filing — “Abstentions and "broker non-votes" will not be counted as votes cast or shares voting on Proposal 3, and will have no effect on the vote.”.
Approval percentages are the company’s own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.
CEO pay ratio
| Ratio (CEO : median employee) | — |
|---|---|
| CEO total compensation | — |
| Median employee compensation | — |
Insider trades since the proxy
Every insider equity transaction reported on Form 4 after the 2025 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.
| Insider | Role | Transaction date | Code | Shares | Price | Value | Security | Source |
|---|---|---|---|---|---|---|---|---|
| Garo H. Armen | Director | 2026-05-01 | A | 4,233 | $4 | $16,255 | Common | Form 4 ↗ |
| Garo H. Armen | Director | 2026-05-15 | A | 4,540 | 4 | 16,253 | Common | Form 4 ↗ |
| Garo H. Armen | Director | 2026-05-29 | A | 4,644 | 4 | 16,254 | Common | Form 4 ↗ |
| Garo H. Armen | Director | 2026-06-12 | A | 4,925 | 3 | 16,253 | Common | Form 4 ↗ |
| Garo H. Armen | Director | 2026-06-26 | A | 5,364 | 3 | 16,253 | Common | Form 4 ↗ |
| Thomas Harrison | Director | 2026-07-01 | A | 8,547 | 4 | 30,624 | Common | Form 4 ↗ |
| Timothy R. Wright | Director | 2026-07-01 | A | 2,267.77 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Garo H. Armen | Director | 2026-07-10 | A | 4,852 | 3 | 16,254 | Common | Form 4 ↗ |
| Marco Tullio Marcucci | Director | 2026-08-05 | A | 7,500 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Timothy R. Wright | Director | 2026-08-05 | A | 50,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Jennifer Buell | Director | 2026-08-05 | A | 200,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Susan Hirsch | Director | 2026-08-05 | A | 50,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Brian Corvese | Director | 2026-08-05 | A | 100,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Steven O'Day | Chief Medical Officer | 2026-08-05 | A | 100,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Thomas Harrison | Director | 2026-08-05 | A | 50,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Garo H. Armen | Director | 2026-08-10 | A | 1,971,500 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Thomas Harrison | Director | 2026-10-01 | A | 4,443 | 7 | 30,626 | Common | Form 4 ↗ |
| Timothy R. Wright | Director | 2026-10-01 | A | 1,178.76 | — | — | Derivative, Class A Common | Form 4 ↗ |
Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.
Sources (57 citations)
Each figure is listed with the filing it comes from, where it appears in that filing, and the value as printed. Any figure can be independently confirmed against the source.
- Section 01, Garo Armen. DEF 14A, filed 2026-04-30. Section “Summary Compensation Table” · page 20. As printed: 1,350,325. View filing ↗
- Section 01, Steven O'Day. DEF 14A, filed 2026-04-30. Section “Summary Compensation Table”. As printed: 902,820. View filing ↗
- Section 01, Christine Klaskin. DEF 14A, filed 2026-04-30. Section “Summary Compensation Table”. As printed: 332,019. View filing ↗
- Section 03, Garo Armen OPTION. DEF 14A, filed 2026-04-30. Section “Grants of Plan-Based Awards for Fiscal Year 2025” · grants of plan-based awards table. View filing ↗
- Section 03, Christine Klaskin OPTION. DEF 14A, filed 2026-04-30. Section “Grants of Plan-Based Awards for Fiscal Year 2025” · grants of plan-based awards table. View filing ↗
- Section 07, pay ratio. 10-K, filed 2026-03-16. Section “CEO Pay Ratio”. As printed: —. View filing ↗
- Section 08, Brian Corvese. DEF 14A, filed 2026-04-30. Section “Director Compensation”. As printed: 375,322. View filing ↗
- Section 08, Timothy R. Wright. DEF 14A, filed 2026-04-30. Section “Director Compensation”. As printed: 199,454. View filing ↗
- Section 08, Thomas Harrison. DEF 14A, filed 2026-04-30. Section “Director Compensation”. As printed: 175,041. View filing ↗
- Section 08, Susan Hirsch. DEF 14A, filed 2026-04-30. Section “Director Compensation”. As printed: 150,035. View filing ↗
- Section 08, Jennifer Buell. DEF 14A, filed 2026-04-30. Section “Director Compensation”. As printed: 0. View filing ↗
- Section 08, Garo H. Armen. DEF 14A, filed 2026-04-30. Section “Director Compensation”. As printed: 0. View filing ↗
- Section 02, Garo H. Armen 2026-05-01. Form 4, filed 2026-05-05. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Garo H. Armen 2026-05-15. Form 4, filed 2026-05-19. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Garo H. Armen 2026-05-29. Form 4, filed 2026-06-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Garo H. Armen 2026-06-12. Form 4, filed 2026-06-16. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Garo H. Armen 2026-06-26. Form 4, filed 2026-06-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Thomas Harrison 2026-07-01. Form 4, filed 2026-07-07. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Timothy R. Wright 2026-07-01. Form 4, filed 2026-07-07. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Garo H. Armen 2026-07-10. Form 4, filed 2026-07-14. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Marco Tullio Marcucci 2026-08-05. Form 4, filed 2026-09-16. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Timothy R. Wright 2026-08-05. Form 4, filed 2026-08-07. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jennifer Buell 2026-08-05. Form 4, filed 2026-08-07. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Susan Hirsch 2026-08-05. Form 4, filed 2026-08-07. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Brian Corvese 2026-08-05. Form 4, filed 2026-08-11. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Steven O'Day 2026-08-05. Form 4, filed 2026-08-07. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Thomas Harrison 2026-08-05. Form 4, filed 2026-08-11. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Garo H. Armen 2026-08-10. Form 4, filed 2026-08-12. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Thomas Harrison 2026-10-01. Form 4, filed 2026-10-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Timothy R. Wright 2026-10-01. Form 4, filed 2026-10-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 06, 2026 vote. Form 8-K, filed 2026-06-23. Item 5.07 · say-on-pay result. As reported: 66.21% (votes for as printed: 12,751,266). View filing ↗
- Section 06, 2025 vote. Form 8-K, filed 2025-06-20. Item 5.07 · say-on-pay result. As reported: 49.89% (votes for as printed: 5,162,339). View filing ↗
- Section 06, 2024 vote. Form 8-K, filed 2024-06-14. Item 5.07 · say-on-pay result. As reported: 88.07% (votes for as printed: 8,811,608). View filing ↗
- Section 01 trend, Δ column (computed). Computed. Δ = current-FY total − prior-FY total per named officer.
- Section 03b vehicle mix (computed). Computed. RSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).
- Section 09b board cost (computed). Computed. Cash 610,000 + equity 0 + all other 0 = 610,000, summed across the director compensation table rows.
- iTeos Therapeutics, Section 10b CEO total. DEF 14A, filed 2025-04-24. CEO total compensation as printed in iTeos Therapeutics's own proxy. As printed: 6,085,657. View filing ↗
- Precigen, Section 10b CEO total. DEF 14A, filed 2026-04-30. CEO total compensation as printed in Precigen's own proxy. As printed: 5,354,329. View filing ↗
- Inhibrx, Section 10b CEO total. DEF 14A, filed 2026-04-23. CEO total compensation as printed in Inhibrx's own proxy. As printed: 2,892,473. View filing ↗
- Voyager Therapeutics, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-28. CEO total compensation as printed in Voyager Therapeutics, Inc.'s own proxy. As printed: 2,508,370. View filing ↗
- ALX Oncology, Section 10b CEO total. DEF 14A, filed 2026-04-20. CEO total compensation as printed in ALX Oncology's own proxy. As printed: 2,470,844. View filing ↗
- Repare Therapeutics, Section 10b CEO total. DEF 14A, filed 2025-04-29. CEO total compensation as printed in Repare Therapeutics's own proxy. As printed: 2,368,837. View filing ↗
- Karyopharm Therapeutics Inc., Section 10b CEO total. DEF 14A, filed 2026-04-13. CEO total compensation as printed in Karyopharm Therapeutics Inc.'s own proxy. As printed: 2,320,902. View filing ↗
- Instil Bio, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-24. CEO total compensation as printed in Instil Bio, Inc.'s own proxy. As printed: 2,256,412. View filing ↗
- Fate Therapeutics, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-24. CEO total compensation as printed in Fate Therapeutics, Inc.'s own proxy. As printed: 2,248,568. View filing ↗
- Precision BioSciences, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-08. CEO total compensation as printed in Precision BioSciences, Inc.'s own proxy. As printed: 2,189,467. View filing ↗
- MacroGenics, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-08. CEO total compensation as printed in MacroGenics, Inc.'s own proxy. As printed: 2,078,854. View filing ↗
- Seres Therapeutics, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-27. CEO total compensation as printed in Seres Therapeutics, Inc.'s own proxy. As printed: 1,775,549. View filing ↗
- Immuneering, Section 10b CEO total. DEF 14A, filed 2026-04-20. CEO total compensation as printed in Immuneering's own proxy. As printed: 1,660,612. View filing ↗
- Mersana Therapeutics, Inc., Section 10b CEO total. DEF 14A, filed 2025-04-29. CEO total compensation as printed in Mersana Therapeutics, Inc.'s own proxy. As printed: 1,613,754. View filing ↗
- Inovio Pharmaceuticals, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-07. CEO total compensation as printed in Inovio Pharmaceuticals, Inc.'s own proxy. As printed: 1,587,155. View filing ↗
- Agenus Inc (subject), Section 10b CEO total. DEF 14A, filed 2026-04-30. CEO total compensation as printed in Agenus Inc's own proxy. As printed: 1,350,325. View filing ↗
- Zentalis Pharmaceuticals, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-30. CEO total compensation as printed in Zentalis Pharmaceuticals, Inc.'s own proxy. As printed: 1,300,731. View filing ↗
- Atara Biotherapeutics, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-24. CEO total compensation as printed in Atara Biotherapeutics, Inc.'s own proxy. As printed: 1,068,069. View filing ↗
- Section 10a, Atara Biotherapeutics, Inc. reciprocity. DEF 14A. Atara Biotherapeutics, Inc. names Agenus Inc in its own disclosed peer group (read from its most recent proxy). View filing ↗
- Section 10a, Inovio Pharmaceuticals, Inc. reciprocity. DEF 14A. Inovio Pharmaceuticals, Inc. names Agenus Inc in its own disclosed peer group (read from its most recent proxy). View filing ↗
- Section 10a, MacroGenics, Inc. reciprocity. DEF 14A. MacroGenics, Inc. names Agenus Inc in its own disclosed peer group (read from its most recent proxy). View filing ↗